Heart Failure 2026: Vutrisiran Data & European Pharma News

Key Takeaways

• Alnylam presented new HELIOS-B analyses at Heart Failure 2026 showing vutrisiran reduced mortality and cardiovascular events by 28% over 36 months in ATTR-CM patients (Alnylam press release).
• Context Therapeutics received FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer on April 2, 2026 (Context Therapeutics).
• NextCure secured FDA Fast Track designation for SIM0505, a CDH6-targeting ADC for platinum-resistant ovarian cancer (NextCure press release).
• Scancell gained FDA Fast Track designation for iSCIB1+ in advanced melanoma, with Phase 3 trial initiation planned for H2 2026 (Scancell).

What Is ATTR-CM and How Does Vutrisiran Work?

Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) is a progressive, life-threatening condition. Abnormal deposits of the transthyretin (TTR) protein accumulate in the heart muscle. This buildup stiffens the heart walls and impairs its ability to pump blood effectively. Patients experience heart failure symptoms that worsen over time.

Vutrisiran (brand name AMVUTTRA) is an RNA interference (RNAi) therapeutic. It works by silencing the TTR gene, which reduces production of the disease-causing protein. The FDA approved vutrisiran for ATTR-CM on March 20, 2025, making it the first therapy approved for both ATTR-CM and hereditary ATTR polyneuropathy (hATTR-PN).

Heart Failure 2026: Key Vutrisiran Data Presented

The European Society of Cardiology's Heart Failure 2026 congress took place May 9–12, 2026, in Barcelona, Spain. Alnylam Pharmaceuticals presented multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran in ATTR-CM patients.

HELIOS-B Efficacy Results

The HELIOS-B trial enrolled 654 patients with wild-type or hereditary ATTR-CM. Over the 36-month double-blind period, vutrisiran demonstrated:

• 28% reduction in risk of all-cause mortality and recurrent cardiovascular events in the overall population
• 33% reduction in the monotherapy population (patients not receiving tafamidis)
• 36% reduction in mortality through 42 months (including open-label extension)
• Consistent benefits in patients with atrial fibrillation (65% of study population)
• Efficacy maintained regardless of concomitant heart failure medications

DemonsTTRate Study Design

Alnylam also presented the design rationale for the DemonsTTRate study. This global, prospective, observational study will enroll more than 2,000 ATTR-CM patients. Researchers will follow participants for up to five years to assess real-world clinical outcomes, treatment patterns, and healthcare utilization. Pablo Garcia-Pavia of Spain presented this during the "Evolving management of cardiomyopathies" session on May 10, 2026.

Which Oncology Therapies Received FDA Fast Track Designations?

The FDA granted Fast Track designations to three oncology therapies in April 2026. These designations recognize the potential of these drugs to address unmet medical needs in serious conditions.

Therapy	Company	Target	Indication	Trial
CTIM-76	Context Therapeutics	CLDN6 x CD3 bispecific	Platinum-resistant ovarian cancer	NCT06515613 (Phase 1)
SIM0505	NextCure	CDH6 ADC	Platinum-resistant ovarian cancer	NCT06792552 (Phase 1)
iSCIB1+	Scancell Holdings	ImmunoBody DNA vaccine	Advanced melanoma	SCOPE Phase 2

CTIM-76 for CLDN6-Positive Cancers

CTIM-76 is a bispecific antibody targeting CLDN6 and CD3. It engages T cells to attack tumor cells expressing CLDN6, a protein enriched in ovarian, endometrial, and testicular cancers. The Phase 1 trial (NCT06515613) is evaluating safety and efficacy in CLDN6-positive advanced or metastatic cancers. Interim data is expected in June 2026. CLDN6 represents a validated therapeutic target with no currently approved treatments.

SIM0505: NextCure's ADC Approach

SIM0505 is an antibody-drug conjugate targeting cadherin-6 (CDH6), which is overexpressed in ovarian cancer with limited expression in healthy tissues. The drug features a proprietary topoisomerase 1 inhibitor payload designed for broad anti-tumor activity and fast systemic clearance. NextCure acquired this program in June 2025 and plans to initiate dose optimization in ovarian cancer patients in Q2 2026.

iSCIB1+ Melanoma Immunotherapy

Scancell's iSCIB1+ is a DNA vaccine from the ImmunoBody platform. In the Phase 2 SCOPE trial, iSCIB1+ combined with ipilimumab and nivolumab demonstrated 77% progression-free survival at 20 months. This represents a significant improvement over standard-of-care benchmarks. The FDA has cleared the Investigational New Drug application for a Phase 3 trial expected to start in H2 2026.

What Is the Hello Tomorrow Global Summit?

The Hello Tomorrow Global Summit takes place June 11–12, 2026, in Amsterdam. This event brings together researchers, entrepreneurs, industrial players, and investors to explore emerging technologies. Sessions cover quantum computing, synthetic biology, and other deeptech innovations shaping the future of healthcare and beyond.

Why Do Fast Track Designations Matter for Patients?

Fast Track designation provides several advantages that can accelerate patient access to new therapies:

1. More frequent interactions with FDA to align development plans
2. Rolling review of portions of the marketing application
3. Eligibility for priority review upon submission
4. Accelerated clinical development timelines

For patients with platinum-resistant ovarian cancer or advanced melanoma, where treatment options remain limited, these designations signal potential new therapeutic avenues.

What Should Investors Watch Next?

• Alnylam's DemonsTTRate study enrollment progress and real-world vutrisiran data
• CTIM-76 Phase 1 interim data expected June 2026
• SIM0505 dose optimization study initiation in Q2 2026
• iSCIB1+ Phase 3 trial initiation in H2 2026
• Additional PFS and OS data from the iSCIB1+ SCOPE study in H1 2027

Frequently Asked Questions

Related Coverage

• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
• Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains
• Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma
• Latest cardiovascular technology news and analysis
• Oncology pipeline updates and regulatory news

Primary Sources

• Alnylam Pharmaceuticals. "Alnylam to Present New Analyses at Heart Failure 2026." BusinessWire, May 4, 2026.
• Alnylam Pharmaceuticals. "Alnylam to Present New Analyses at Heart Failure 2026." Investor Relations.
• Context Therapeutics. "Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation." April 2, 2026.
• Context Therapeutics. "CTIM-76 Clinical Overview."
• ClinicalTrials.gov. "Study of CTIM-76 in CLDN6 Positive Advanced or Metastatic Solid Tumors." NCT06515613.
• NextCure, Inc. "NextCure Receives Fast Track Designation for SIM0505." April 2026.
• ClinicalTrials.gov. "Study of SIM0505 in Advanced Solid Tumors." NCT06792552.
• Scancell Holdings. "iSCIB1+ Program Information."
• European Society of Cardiology. "Heart Failure 2026 Congress Information."